Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.

Cancer research - 1 Sept 2014

Esmaeili Morteza, Hamans Bob C, Navis Anna C, van Horssen Remco, Bathen Tone F, Gribbestad Ingrid S, Leenders William P, Heerschap Arend

Abstract excerpt

Many patients with glioma harbor specific mutations in the isocitrate dehydrogenase gene IDH1 that associate with a relatively better prognosis. IDH1-mutated tumors produce the oncometabolite 2-hydroxyglutarate. Because IDH1 also regulates several pathways leading to lipid synthesis, we hypothesized that IDH1-mutant tumors have an altered phospholipid metabolite profile that would impinge on tumor pathobiology....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biomarkers, Tumor
Share to Ethanolamines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Glioma

Share to Isocitrate Dehydrogenase

Share to Magnetic Resonance Spectroscopy

Share to Mice, Inbred BALB C

Share to Mice, Nude

Share to Phospholipids

Source

Identifiers

PMID: 25005896
DOI: 10.1158/0008-5472.CAN-14-0008

Genes

IDH1

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IDH1 R132H mutation generates a distinct phospholipid metabolite profile in glioma.PMID 25005896Read ↗

A Noninvasive Comparison Study between Human Gliomas with IDH1 and IDH2 Mutations by MR SpectroscopySemantic proximity Read ↗

Magnetic resonance of 2-hydroxyglutarate in IDH1-mutated low-grade gliomas.Semantic proximity Read ↗

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma.Semantic proximity Read ↗

Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations.Semantic proximity Read ↗

Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.Semantic proximity Read ↗

Metabolic reprogramming in mutant IDH1 glioma cells.Semantic proximity Read ↗

Integrated Metabolomics and Lipidomics Analyses Reveal Metabolic Reprogramming in Human Glioma with IDH1 MutationSemantic proximity Read ↗

IDH1 Mutations Induce Organelle Defects Via Dysregulated PhospholipidsSemantic proximity Read ↗

Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy.Semantic proximity Read ↗

Imaging biomarkers for detecting IDH mutations and monitoring response to novel targeted therapies: Current insights and future perspectives.Semantic proximity Read ↗

IDH1 mutations induce organelle defects via dysregulated phospholipids.Semantic proximity Read ↗

Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.